UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934


Date of report (Date of earliest event reported): May 7, 2013

ACCESS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)


Delaware
0-9314
83-0221517
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
     


2600 Stemmons Freeway, Suite 176
Dallas, TX 75207
(Address of principal executive offices) (Zip Code)
 
(214) 905-5100
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 
 

 

 
Item 5.07.  Submission of Matters to a Vote of Security Holders.

The annual meeting of stockholders of Access Pharmaceutical, Inc. (the “Company”) was held on May 7, 2013.  The following matters were acted upon:

1.  ELECTION OF DIRECTORS

Mark J. Ahn and Mark J. Alvino were both elected to serve as directors of the Company until their successors are duly elected and qualified.  The results of the election of directors are as follows:

Nominee
Votes For
Votes Withheld
 Broker Non-Votes
Mark J. Ahn
73,971,987
1,695,162
 10,448,061
Mark J. Alvion
73,977,568
1,689,581
 10,448,061
 
 
2.  APPROVAL ON AN ADVISORY BASIS OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.
 
Approval on an advisory basis of the compensation of the to the Company's named executive officers was approved by the following votes:

Votes For
Votes Against
Abstain
Broker Non-Votes
74,350,691
1,296,391
20,066
10,448,061
 
 
3.  APPROVAL ON AN ADVISORY VOTE ON THE FREQUENCY OF ADVISORY VOTES ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

Approval on an advisory basis on the frequency of advisory votes on the compensation of the Company's named executive officers was approved for every three years by the following votes:

Votes For 1 Year
Votes For 2 Years
Votes For 3 Years
 Abstain
Broker Non-Votes
1,497,234
255,794
72,161,370
 1,752,751
10,448,061
 
 
4.  APPROVAL TO THE CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 130,000,000 SHARES TO 200,000,000 SHARES.

 
Approval to the Certificate of Incorporation to increase the number of authorized shares of common stock was approved by the following votes:

Votes For
Votes Against
Abstain
Broker Non-Votes
74,240,325
1,425,118
1,705
10,448,061
 
 
5.  APPROVAL TO THE COMPANY'S 2005 EQUITY INCENTIVE PLAN.
 
Approval to the Company's 2005 Equity Incentive Plan to increase the number of authorized shares of common stock from 5,000,000 shares ot 25,000,000 was approved by the following votes:

Votes For
Votes Against
Abstain
Broker Non-Votes
73,659,485
10,748,065
7,712
10,448,061
 
 
6.  RATIFICATION OF APPOINTMENT OF WHITLEY PENN LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2013.

 Ratification of the appointment of Whitley Penn LLP as the independent registered public accounting firm of the Company was approved by the following votes:

Votes For
Votes Against
Abstain
Broker Non-Votes
84,241,904
1,759,115
114,171
0



 
 

 

SIGNATURE

 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
Access Pharmaceuticals, Inc.    
(Registrant)                                

By:   /s/ Stephen B. Thompson 
              Stephen B. Thompson 
       Vice President and 
       Chief Financial Officer 

Dated  May 9, 2012